News - Page 18

The initial part of the up-to-$339 million funding will largely be used to establish U.S. manufacturing for the non-vaccine flu preventive candidate, with additional options tied to further clinical studies, Cidara said.

Vaxcyte is paying Thermo Fisher Scientific up to $1 billion to access vaccine fill-finish capacity at the CDMO’s production facility in Greenville, North Carolina. Vaxcyte positioned the deal as a “long-term U.S.

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B financing round that will be used to expand the company’s DNA synthesis production capacity in the U.S.